Oligonucleotides, Antisense
"Oligonucleotides, Antisense" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize.
| Descriptor ID |
D016376
|
| MeSH Number(s) |
D13.150.480 D13.444.600.150.640 D13.695.578.424.480 D27.720.470.530.600.150.640
|
| Concept/Terms |
Oligonucleotides, Antisense- Oligonucleotides, Antisense
- Antisense Oligonucleotides
- Anti-Sense Oligonucleotides
- Anti Sense Oligonucleotides
- Oligonucleotides, Anti-Sense
|
Below are MeSH descriptors whose meaning is more general than "Oligonucleotides, Antisense".
Below are MeSH descriptors whose meaning is more specific than "Oligonucleotides, Antisense".
This graph shows the total number of publications written about "Oligonucleotides, Antisense" by people in this website by year, and whether "Oligonucleotides, Antisense" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 1 | 3 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 2 | 3 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 3 | 3 |
| 2005 | 1 | 2 | 3 |
| 2006 | 1 | 1 | 2 |
| 2007 | 2 | 1 | 3 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 3 | 2 | 5 |
| 2016 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 2 | 2 | 4 |
| 2024 | 1 | 1 | 2 |
| 2025 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oligonucleotides, Antisense" by people in Profiles.
-
Recent advances in RNA-based therapeutics for neurodevelopmental disorders. Curr Opin Genet Dev. 2025 Jun; 92:102339.
-
Foamy monocytes and atherogenesis in mice with combined hyperlipidemia and effects of antisense knockdown of apoCIII. J Lipid Res. 2025 Apr; 66(4):100763.
-
Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA. Atherosclerosis. 2025 Apr; 403:119114.
-
Modeling antisense oligonucleotide therapy in MECP2 duplication syndrome human iPSC-derived neurons reveals gene expression programs responsive to MeCP2 levels. Hum Mol Genet. 2024 11 08; 33(22):1986-2001.
-
Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy. J Exp Clin Cancer Res. 2024 Mar 06; 43(1):70.
-
The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma. Mol Cancer. 2024 02 22; 23(1):40.
-
Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment. Oncotarget. 2023 05 26; 14:543-560.
-
ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome. Hepatology. 2023 11 01; 78(5):1337-1351.
-
Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer. Cancer Immunol Res. 2023 04 03; 11(4):486-500.
-
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial. Lancet Neurol. 2023 03; 22(3):218-228.